Literature DB >> 1398956

Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.

K L Kotloff1, S S Wasserman, S O'Donnell, G A Losonsky, S J Cryz, M M Levine.   

Abstract

We conducted a double-blind, placebo-controlled, randomized crossover study to evaluate the safety and immunogenicity of a single 5 x 10(8)-CFU dose of live oral recombinant cholera vaccine CVD 103-HgR in 94 North American adults. The vaccine was well tolerated without associated adverse reactions. Despite minimal fecal excretion of vaccine, 97% of subjects exhibited serum vibriocidal antibody and 72% had antitoxin responses.

Mesh：

Substances：

Year:  1992        PMID： 1398956      PMCID： PMC257485          DOI： 10.1128/iai.60.10.4430-4432.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  12 in total

1.  Recombinant attenuated Vibrio cholerae strains used as live oral vaccines.

Authors:  J B Kaper; M M Levine
Journal:  Res Microbiol       Date:  1990 Sep-Oct       Impact factor: 3.992

2.  Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand.

Authors:  P Su-Arehawaratana; P Singharaj; D N Taylor; C Hoge; A Trofa; K Kuvanont; S Migasena; P Pitisuttitham; Y L Lim; G Losonsky
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

3.  Cholera in Africa: lessons on transmission and control for Latin America.

Authors:  R I Glass; M Claeson; P A Blake; R J Waldman; N F Pierce
Journal:  Lancet       Date:  1991-09-28       Impact factor: 79.321

4.  Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors:  M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

5.  Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults.

Authors:  S J Cryz; M M Levine; J B Kaper; E Fürer; B Althaus
Journal:  Vaccine       Date:  1990-12       Impact factor: 3.641

6.  Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.

Authors:  S Migasena; P Pitisuttitham; B Prayurahong; P Suntharasamai; W Supanaranond; V Desakorn; U Vongsthongsri; B Tall; J Ketley; G Losonsky
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

7.  Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques.

Authors:  M M Levine; J B Kaper; D Herrington; G Losonsky; J G Morris; M L Clements; R E Black; B Tall; R Hall
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

8.  Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine.

Authors:  M M Levine; R E Black; M L Clements; C Lanata; S Sears; T Honda; C R Young; R A Finkelstein
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

9.  Selective vs. nonselective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories.

Authors:  M B Rennels; M M Levine; V Daya; P Angle; C Young
Journal:  J Infect Dis       Date:  1980-09       Impact factor: 5.226

10.  Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology.

Authors:  M M Levine; C R Young; R E Black; Y Takeda; R A Finkelstein
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948
View more
  22 in total

1.  Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.

Authors:  D N Taylor; J L Sanchez; J M Castro; C Lebron; C M Parrado; D E Johnson; C O Tacket; G A Losonsky; S S Wasserman; M M Levine; S J Cryz
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.

Authors:  Wilbur H Chen; Richard N Greenberg; Marcela F Pasetti; Sofie Livio; Michael Lock; Marc Gurwith; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

3.  An overview of VaxchoraTM, a live attenuated oral cholera vaccine.

Authors:  Tarun Saluja; Vijayalaxmi V Mogasale; Jean-Louis Excler; Jerome H Kim; Vittal Mogasale
Journal:  Hum Vaccin Immunother       Date:  2019-09-20       Impact factor: 3.452

Review 4.  Cholera.

Authors:  Jason B Harris; Regina C LaRocque; Firdausi Qadri; Edward T Ryan; Stephen B Calderwood
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

5.  Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.

Authors:  H Kollaritsch; E Furer; C Herzog; G Wiedermann; J U Que; S J Cryz
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

Review 6.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.

Authors:  E Gotuzzo; B Butron; C Seas; M Penny; R Ruiz; G Losonsky; C F Lanata; S S Wasserman; E Salazar; J B Kaper
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Oral cholera vaccine well tolerated.

Authors:  P Barrett; P Clarke; S Cryz
Journal:  BMJ       Date:  1993-11-27

Review 9.  Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

Authors:  Myron M Levine
Journal:  BMC Biol       Date:  2010-10-04       Impact factor: 7.431

10.  Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.

Authors:  S J Cryz; J U Que; M M Levine; G Wiedermann; H Kollaritsch
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.